Table 4

Mean pharmacokinetic parameters of [131I]Sibrotuzumab based on total radioactivity

Dose group (mg/m2)naCmax (μg/ml)CL (ml/h)Vc (liter)Vss (liter)t1/2α (h)t1/2β (day)AUC (μg∗h/ml)AUCβ (%)
516Mean2.6764.53.434.176.882.1215494.0
SD0.33617.20.6330.7447.510.8135.59.40
1011Mean5.4762.93.634.188.702.2534593.3
SD0.86527.30.9400.8878.740.851099.39
256Mean12.1264.54.605.8513.742.9488387.7
SD1.506.640.660.8810.510.7013612.78
5012Mean29.530.93.154.6413.05.21330092.6
SD3.039.970.3180.80310.22.408816.90
  • a n indicates the number of single dose data sets used that were not affected by HAHA development. Includes data after infusions 1, 5, and 9 for each subject when available, and data from the additional treatment cycles of patient 140 in the 5 mg/m2 dose group.